This article is more than 5 years old. Information may no longer be current.
ASH elects four committee members
Click Here to Manage Email Alerts
David A. Williams
Stephanie J. Lee
The American Society of Hematology elected four new members to its executive committee. Their terms begin in January.
David A. Williams, MD, will serve a 1-year term as vice president, followed by successive terms as president-elect and president. Stephanie J. Lee, MD, MPH, will serve a four-year term as secretary. Jonathan D. Licht, MD, and Margaret A. Shipp, MD, will serve four-year terms as councillors.
Jonathan D. Licht
Margaret A. Shipp
“Each of these individuals is extremely well respected in our field and has already contributed a great deal to the society,” Armand Keating, MD, the 2011 ASH president, said in a press release. “I have every confidence in these newly elected society leaders to further ASH’s commitment to move hematology forward during this very exciting time.”
Williams is chief of hematology/oncology and director of translational research at Children’s Hospital Boston, as well as associate chairman of the department of pediatric oncology at Dana-Farber Cancer Institute. His interests include molecular hematopoiesis and gene transfer into hematopoietic stem cells, as well as the clinical care of children with hematologic diseases.
Lee is a professor of medical oncology at the University of Washington School of Medicine in Seattle, as well as an attending physician in the hematopoietic cell transplantation program at Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance. Her interests include outcomes and health services research in hematologic malignancies and allogeneic hematopoietic cell transplantation, as well as late effects of HCT, specifically chronic graft-versus-host disease.
Licht is the Johanna Dobe Professor of Medicine and chief of the division of hematology/oncology at Northwestern University Feinberg School of Medicine, as well as associate director of clinical sciences at Northwestern’s Robert H. Lurie Comprehensive Cancer Center. His interests include epigenetics and aberrant gene expression in hematologic malignancies, including acute promyelocytic leukemia, large cell lymphoma, multiple myeloma and myeloproliferative neoplasms.
Shipp is chief of the division of hematologic neoplasia in the department of medical oncology at Dana-Farber Cancer Institute, director of the Lymphoma Program at Dana-Farber/Harvard Comprehensive Cancer Center, and an attending physician in the Stem Cell Transplantation Program at Dana-Farber/Brigham and Women’s Cancer Center in Boston. Her interests include clinical and molecular heterogeneity of large B-cell lymphomas and Hodgkin’s lymphoma, as well as the identification of unique lymphoma subtypes amenable to targeted therapy and mechanisms of immune evasion.